© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 08, 2022
Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.
A higher percentage of participants in the pooled dulaglutide group had a glycated hemoglobin level of
June 07, 2022
Data show the mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg, and -20.9% with 15-mg dose, compared to -3.1% with placebo.
The late-breaking data show SGLT2is are underutilized in patients with heart failure with or without type 2 diabetes despite guideline recommendations.
The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.
June 05, 2022
The mean time below range following exercise sessions was significantly lower with IGlar U300 compared to IDEG at the 100% dose.
The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.
Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.
However, the post-hoc analysis found a greater variability in HbA1c levels was associated with increased risk of cardiorenal outcomes.
The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.
Study Suggests Sickle Cell Trait as an Adverse Prognostic Factor for COVID-19
Atherosclerotic Plaque Found Highly Prevalent in Older Population in China
Vurolenatide Showing Promise Treating Short Bowel Syndrome